ArticleJournal of cancer research and clinical oncology2010
Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma.
Article in Journal of cancer research and clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review.International journal of clinical and experimental pathology · 2014Pooled it
- Immunomodulatory Gene-Splicing Dysregulation in Tumorigenesis: Unmasking the Complexity.Molecules (Basel, Switzerland) · 2023Review
- Extracellular matrix and its therapeutic potential for cancer treatment.Signal transduction and targeted therapy · 2021Review
- Correlation analysis of expression and prognosis of TTF-1 and CD44v6 in undifferentiated lung carcinoma.Oncology letters · 2019Article
- Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention.Journal of human genetics · 2018Review
- CD44 promotes cell proliferation in non-small cell lung cancer.Oncology letters · 2018Article
- Evaluation of the Correlation between CD44, Tumor Prognosis and the 5-Year Survival Rate in Patients with Oral Tongue SCC.Iranian journal of otorhinolaryngology · 2016Article
- Overexpression of CD44 is associated with the occurrence and migration of non-small cell lung cancer.Molecular medicine reports · 2016Article
- Association of cancer stem cell markers genetic variants with gallbladder cancer susceptibility, prognosis, and survival.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Cell surface marker profiling of human tracheal basal cells reveals distinct subpopulations, identifies MST1/MSP as a mitogenic signal, and identifies new biomarkers for lung squamous cell carcinomas.Respiratory research · 2014Article
- Expression and association of CD44v6 with prognosis in T2-3N0M0 esophageal squamous cell carcinoma.Journal of thoracic disease · 2014Article
- CD44 gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan.PloS one · 2014Article
- Alpha-CaMKII plays a critical role in determining the aggressive behavior of human osteosarcoma.Molecular cancer research : MCR · 2013Article
- Expression of CD44v6 and Its Association with Prognosis in Epithelial Ovarian Carcinomas.Pathology research international · 2012Article
- Prognostic significance of CD44s expression in resected non-small cell lung cancer.BMC cancer · 2011Article
- Prognostic relevance of β-catenin expression in T2-3N0M0 esophageal squamous cell carcinoma.World journal of gastroenterology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeExpression of CD44 and its variants has been shown to be relevant to tumor progression in various human malignancies. We evaluated the expression of CD44v6 in the primary lesions of stage I non-small cell lung cancer (NSCLC) and correlated the expression level to its prognosis.
methodsThe expression of CD44v6, measured by immunohistochemistry, was assessed in the tumor specimens from 190 patients with stage I NSCLC. Each slide was assigned a score: the average of the score of tumor cells staining multiplied by the score of staining intensity. And depending on the cut-off score based on receiver operating characteristic (ROC) curve analysis, the CD44v6 expression was categorized into high- and low-level groups, which were then correlated directly with the clinical outcomes.
resultsThe high expression of CD44v6 was detected more frequently in the squamous cell carcinoma (38 of 71 patients, 53.5%) than in the other types of carcinoma (p < 0.05). The Kaplan-Meier survival curves showed that high level expression of CD44v6 indicated a better post-operative survival (p = 0.006), especially for stage IB disease (p = 0.049) and squamous cell carcinoma (p = 0.029). The multivariate analysis also confirmed that the expression of CD44v6 was an independent prognostic indicator (p = 0.011).
conclusionsCD44v6 might be correlated with histogenesis of NSCLC, and its decreased expression may be an adverse prognostic indicator for the patients with stage I NSCLC, especially for those with stage IB diseases. Patients of this subgroup might need adjuvant therapy additionally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.